Barclays analyst Carter Gould upgrades Amgen (NASDAQ:AMGN) from Underweight to Equal-Weight and raises the price target from $230 to $300.
Barclays Upgrades Amgen to Equal-Weight, Raises Price Target to $300
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.